TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY

Size: px
Start display at page:

Download "TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY"

Transcription

1 TWO BY TWO: A METHODOLOGICAL PERSPECTIVE ON THE USE OF EVIDENCE TO SUPPORT THE VALUE OF A HEALTH TECHNOLOGY A/Prof Tracy Merlin Adelaide Health Technology Assessment (AHTA) School of Population Health University of Adelaide

2 HEALTH TECHNOLOGY

3 INDUSTRY PERCEPTION OF TECHNOLOGY VALUE (2X2) Cash cow hold & milk the technology Stars harvest technology s success Question mark invest? or divest? Dog divest from technology The Boston Consulting Group (BCG) Portfolio Matrix

4 DETERMINING TECHNOLOGY VALUE TO THE HEALTH SYSTEM Health Technology Assessment (HTA) is a form of policy research that systematically examines the short- and long-term consequences, in terms of health and resource use, of the application of a health technology, a set of related technologies or a technology related issue. Henshall et al. (1997)

5 Source:

6

7 METHODS OF EVIDENCE GENERATION. I. Strategic development of primary research (studies) on the technology fit-for-purpose (should address both regulatory and reimbursement requirements) more certainty in policy outcome but resource intensive

8 GREEN PARK COLLABORATIVE AHTA, University of Adelaide 8

9 DECIDE NETWORK Dr Scott Smith, AHRQ Center for Outcomes & Evidence 2009

10 WHAT DOES DECIDE PRIMARILY DO? A. Analyse existing health care databases to compare the effectiveness & outcomes of treatment. B. Analyse existing disease, device, and other registries. C. Conduct methodological studies to improve research on clinical effectiveness of treatments.

11 POINTS FOR PRIMARY EVIDENCE GENERATION Target is: local market focus evidence generation to regional requirements global market broadly applicable evidence generation but tailoring to regional HTA requirements (studies with multiple comparators, multiple patient indications, different relevant health outcomes) Engage with policy/hta sector: to determine areas of clinical need prior to technology development prior to commencing human studies (research design advice RCTs are not always needed) possibilities of coverage with evidence development in areas of high need Tap existing resources academia and clinicians in the field, existing trial networks and administrative datasets / registers

12 METHODS OF EVIDENCE GENERATION. II. Collate or adapt published evidence from other sources in a manner that supports the value proposition and addresses the policy question less certainty in policy outcome (applicability of evidence may be poor) but less resource intensive

13 SCIENTIFIC EVIDENCE Source:

14 SYSTEMATIC VS. NARRATIVE LITERATURE REVIEWS Scientific approach Comprehensive search for all relevant primary research Study selection criteria determined at outset Explicit pre-defined methods of appraisal and synthesis Meta-analysis may be used Review is replicable Approach depends on authors inclination Search any databases Author gets to select studies using any criteria (bias) Methods not usually specified Vote count or narrative summary Cannot replicate review

15 ECONOMIC MODELLING

16 POINTS FOR SECONDARY EVIDENCE GENERATION What is the clinical need for the technology? What are the patientrelevant benefits and harms of the technology? Define the clinical pathway: how will the technology be used in clinical practice in the targeted health system? in what setting will it be used? in what patient groups? what existing technologies will it replace or supplement? Are there any other interventions associated with use of the technology? Who will deliver the technology? Is additional training required? Systematically review the available clinical evidence. Does it address all of the points above? Can it be extrapolated from elsewhere? Model clinical effects and costs of delivering technology as described above.

17 POLICY PERCEPTION OF TECHNOLOGY VALUE (2X2) SW trade-off between costs/benefits NW reject technology NE trade-off between costs/benefits SE accept technology Petrou S, and Gray A BMJ 2011;342:bmj.d by British Medical Journal Publishing Group The cost effectiveness plane

18 QUESTIONS?

December Eucomed HTA Position Paper UK support from ABHI

December Eucomed HTA Position Paper UK support from ABHI December 2008 Eucomed HTA Position Paper UK support from ABHI The Eucomed position paper on Health Technology Assessment presents the views of the Medical Devices Industry of the challenges of performing

More information

SHTG primary submission process

SHTG primary submission process Meeting date: 24 April 2014 Agenda item: 8 Paper number: SHTG 14-16 Title: Purpose: SHTG primary submission process FOR INFORMATION Background The purpose of this paper is to update SHTG members on developments

More information

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as: HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually

More information

The Health Information Future: Evolution and/or Intelligent Design?

The Health Information Future: Evolution and/or Intelligent Design? The Health Information Future: Evolution and/or Intelligent Design? North American Association of Central Cancer Registries Conference Regina, Saskatchewan June 14, 2006 Steven Lewis Access Consulting

More information

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities

Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Health Technology Assessment of Medical Devices in Low and Middle Income countries: challenges and opportunities Aleksandra Torbica, Carlo Federici, Rosanna Tarricone Centre for Research on Health and

More information

EU s Innovative Medical Technology and EMA s Measures

EU s Innovative Medical Technology and EMA s Measures EU s Innovative Medical Technology and EMA s Measures 27 October 2017 Summit symposium 25-27 October 2017, Kyoto, Japan Presented by Guido Rasi Executive Director, European Medicines Agency (EMA) An agency

More information

Andalusian Agency for Health Technology Assessment (AETSA)

Andalusian Agency for Health Technology Assessment (AETSA) Andalusian Agency for Health Technology Assessment (AETSA) Seville, 22 nd of July, 2016 Comments on the concept paper Facilitating the translation of advanced therapies to patients in Europe 1 Introduction

More information

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry

More information

Biomedical Innovation Has Science Overtaken the System?

Biomedical Innovation Has Science Overtaken the System? Adaptive Pathways for Transformative Medicinal Products. A New Paradigm with the Enhanced Application of Real-World Evidence? ISPOR 20 th Annual European Congress, Glasgow, Scotland Issue Panel 21, Wednesday,

More information

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI

Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI Health Technology Assessment: What are the key challenges to assess medical devices? Rosanna Tarricone, PhD Director CERGAS Scientific Director EHTI SAMED, Annual Conference, May 29 th 2014 From «Does

More information

ABHI Response to the Kennedy short study on Valuing Innovation

ABHI Response to the Kennedy short study on Valuing Innovation ABHI Response to the Kennedy short study on Valuing Innovation Introduction 1. The Association of British Healthcare Industries (ABHI) is the industry association for the UK medical technology sector.

More information

Translational scientist competency profile

Translational scientist competency profile C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective

More information

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint 'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented

More information

Decision Determinants Guidance Document

Decision Determinants Guidance Document Decision Determinants Guidance Document The Ontario Health Technology Advisory Committee (OHTAC) Decision-Making Process for the Development of Evidence-Based Recommendations Revised September 2010 Medical

More information

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use

Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Strategies for Knowledge Translation and Mobilization to Inform Hospital Health Technology Use Rosmin Esmail MSc, CHE Director, Knowledge Translation Research, Analytics and Innovation Portfolio Alberta

More information

National Coordinated Registry Network (CRN) Think-tank

National Coordinated Registry Network (CRN) Think-tank National Coordinated Registry Network (CRN) Think-tank The Value of Real World Data for Innovation within FDA What can CRNs offer? Murray Sheldon, MD Associate Director for Technology and Innovation FDA/CDRH

More information

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes

CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes CADTH HEALTH TECHNOLOGY MANAGEMENT PROGRAM Horizon Scanning Products and Services Processes Service Line: Health Technology Management Program Version: 1.0 Publication Date: September 2017 Report Length:

More information

A Comprehensive Statewide Study of Gambling Impacts: Implications for Public Health

A Comprehensive Statewide Study of Gambling Impacts: Implications for Public Health A Comprehensive Statewide Study of Gambling Impacts: Implications for Public Health Rachel A. Volberg 2 nd Annual Maryland Conference on Problem Gambling June 13, 2014 Acknowledgement We would like to

More information

Innovation in HTA: What is the additional value?

Innovation in HTA: What is the additional value? Innovation in HTA: What is the additional value? Stirling Bryan Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health Research Institute School of Population & Public Health, UBC My co-authors

More information

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation Reflection Paper on synergies between regulatory and HTA issues DG SANTE Unit B4 Medical products: safety, quality, innovation STAMP meeting, 28 June 2016 Outline Aim of the Reflection Paper Drafting process

More information

WHO Workshop, Bangkok, Health Technology Assessment

WHO Workshop, Bangkok, Health Technology Assessment WHO Workshop, Bangkok, 11.09.2010 Health Technology Assessment 1. Introduction to Health Technology Assessment (HTA) Berit Mørland, Norway 2. HTA & Government Keng Ho PWEE, Singapore 3. HTA and Clinical

More information

HTA, the roadmap from investment to disinvestment

HTA, the roadmap from investment to disinvestment HTA, the roadmap from investment to disinvestment Dr. Iñaki Gutiérrez-Ibarluzea Secretary of HTAi Osteba. Osasun Teknologien Ebaluazioaren Zerbitzua. Basque Office for HTA. Osasun Saila Ministry for Health

More information

EMA experience with the review of digital technology proposals in medicine development programmes

EMA experience with the review of digital technology proposals in medicine development programmes EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency

More information

Digital Health Startups A FirstWord ExpertViews Dossier Report

Digital Health Startups A FirstWord ExpertViews Dossier Report AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in

More information

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA EUnetHTA European network for Health Technology Assessment Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA University of Tokyo, October 24,

More information

Issues in Emerging Health Technologies Bulletin Process

Issues in Emerging Health Technologies Bulletin Process Issues in Emerging Health Technologies Bulletin Process Updated: April 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The

More information

Adaptation of HTA reports: an effective way to use limited resources?

Adaptation of HTA reports: an effective way to use limited resources? Adaptation of HTA reports: an effective way to use limited resources? Iñaki Gutiérrez-Ibarluzea, Osteba, Basque Office for HTA. Ministry for Health, Basque Government Introducing the Basque Country Basque

More information

The UK Prevention Research Partnership (UKPRP): Vision, objectives and rationale

The UK Prevention Research Partnership (UKPRP): Vision, objectives and rationale 1 The UK Prevention Research Partnership (UKPRP): Vision, objectives and rationale This document sets out the vision and objectives for the UKPRP. It includes outline information on the research funding

More information

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark EUnetHTA European network for Health Technology Assessment DATABASES, REGISTRIES AND OTHER DATA CAPTURE TOOLS: HOW CAN WE AVOID MULTIPLICITY AND CREATE AN INTEGRATED DATA-CAPTURE APPROACH ALONG THE PRODUCT

More information

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation

Doing, supporting and using public health research. The Public Health England strategy for research, development and innovation Doing, supporting and using public health research The Public Health England strategy for research, development and innovation Draft - for consultation only About Public Health England Public Health England

More information

Health Technology Assessment and the European Network for HTA

Health Technology Assessment and the European Network for HTA Health Technology Assessment and the European Network for HTA www.eunethta.eu Marcial Velasco Garrido, Technische Universität Berlin for the European Network for HTA, EUnetHTA Outline What is Health Technology

More information

Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools

Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools pscanner All Hands Symposium 2016 Kari A. Stephens, PhD Psychiatry & Behavioral Sciences Biomedical

More information

Research Development Request - Profile Template. European Commission

Research Development Request - Profile Template. European Commission Research Development Request - Profile Template European Commission Research Development Request Profile The following table can be used as a template for drafting a Research Development Request profile.

More information

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered? 3.3 Assessment: National health technology assessment unit 3.3.1 Introduction Health systems throughout the world are struggling with the challenge of how to manage health care delivery in resource-constrained

More information

Supporting Innovation through Regulation and Science

Supporting Innovation through Regulation and Science Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers

More information

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients?

New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? New methods, how could Norway speed up Health Technology Assessment (HTA) to the benefit of health industry, policy-makers, clinicians and patients? Department director Øyvind Melien Reviews and HTA, Norwegian

More information

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on

More information

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 European Network for Health Technology Assessment (EUnetHTA) Joint Action 3 Zoe Garrett, Senior Technical Adviser Lead WP7 National Implementation and Impact National Institute for Health and Care Excellence

More information

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer 13 December 2007 A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer Project Team Leela Barham Michelle Ng NERA Economic Consulting 15 Stratford Place London W1C 1BE United Kingdom Tel:

More information

Outline of Presentation

Outline of Presentation WHAT IS VALUE IN HEALTH DOING FOR ITS AUTHORS? Michael Drummond C. Daniel Mullins Co-Editors-in-Chief Value in Health Outline of Presentation Scope and Overview of Value in Health What Value in Health

More information

Navigating the Healthcare Innovation Cycle

Navigating the Healthcare Innovation Cycle Navigating the Healthcare Innovation Cycle Introduction: CIMIT s 20 + years of experience in facilitating more than 600 projects is that innovation in Healthcare is a learnable, teachable process, which

More information

Driving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif

Driving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif Connect and Catalyse Medicines and Healthcare the Global perspective (+10 years) Zahid Latif % GDP spent on health OECD countries spent nearly $3.5trn in 2005 ($4.6 trillion in 2008) on healthcare services

More information

IoT in Health and Social Care

IoT in Health and Social Care IoT in Health and Social Care Preserving Privacy: Good Practice Brief NOVEMBER 2017 Produced by Contents Introduction... 3 The DASH Project... 4 Why the Need for Guidelines?... 5 The Guidelines... 6 DASH

More information

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection Digital therapy technology endorsement for IAPT project eligibility and prioritisation criteria NICE has been commissioned by NHS England to assess selected, digitally enabled therapies for depression

More information

Centre for the Advancement of Health Innovations (CAHI)

Centre for the Advancement of Health Innovations (CAHI) Centre for the Advancement of Health Innovations (CAHI) Excellence in Clinical Innovation and Technology Evaluation Monday, April 16 th, 2012 The Old Mill Inn and Spa, Toronto ON Leslie Levin MB, MD, FRCP

More information

National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs

National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs National Medical Device Evaluation System: CDRH s Vision, Challenges, and Needs Jeff Shuren Director, CDRH Food and Drug Administration Center for Devices and Radiological Health 1 We face a critical public

More information

Compass. Review of the evidence on knowledge translation and exchange in the violence against women field: Key findings and future directions

Compass. Review of the evidence on knowledge translation and exchange in the violence against women field: Key findings and future directions Compass Research to policy and practice April 2015 Review of the evidence on knowledge translation and exchange in the violence against women field: Key findings and future directions Parenting Research

More information

Draft Plan of Action Chair's Text Status 3 May 2008

Draft Plan of Action Chair's Text Status 3 May 2008 Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background

More information

A meta-narrative review of electronic patient records

A meta-narrative review of electronic patient records A meta-narrative review of electronic patient records Henry W W Potts, Trish Greenhalgh, Deborah Swinglehurst, Pippa Bark & Geoff Wong UCL Medical School 9 th Annual Colloquium of the Campbell Collaboration,

More information

9 October Opportunities to Promote Data Sharing UCL and the YODA Project. Emma White. Associate Director

9 October Opportunities to Promote Data Sharing UCL and the YODA Project. Emma White. Associate Director 9 October 2015 Opportunities to Promote Data Sharing UCL and the YODA Project Emma White Associate Director Overview - Administrative Data Research Network (ADRN) - Administrative Data Research Centre

More information

Creating a Vision for Health Literacy s Future: The Research Agenda

Creating a Vision for Health Literacy s Future: The Research Agenda Creating a Vision for Health Literacy s Future: The Research Agenda The 8th Annual Health Literacy Research Conference Bethesda, Maryland October 14, 2016 1 Today s Agenda Introduction Michael Villaire

More information

Early HTA to inform value driven market access and reimbursement planning

Early HTA to inform value driven market access and reimbursement planning Early HTA to inform value driven market access and reimbursement planning Lotte MG Steuten, PhD Associate Prof. Health Technology & Services Research Program Director Health Sciences University of Twente,

More information

Why Randomize? Jim Berry Cornell University

Why Randomize? Jim Berry Cornell University Why Randomize? Jim Berry Cornell University Session Overview I. Basic vocabulary for impact evaluation II. III. IV. Randomized evaluation Other methods of impact evaluation Conclusions J-PAL WHY RANDOMIZE

More information

Ansgar Hebborn Hoffmann-La Roche, Basel, Switzerland

Ansgar Hebborn Hoffmann-La Roche, Basel, Switzerland How Should a Societal Perspective in Economic Evaluation be Implemented? Ansgar Hebborn Hoffmann-La Roche, Basel, Switzerland ISPOR Amsterdam, 11 November 2014 The need to take a societal perspective How

More information

Building Collaborative Networks for Innovation

Building Collaborative Networks for Innovation Building Collaborative Networks for Innovation Patricia McHugh Centre for Innovation and Structural Change National University of Ireland, Galway Systematic Reviews: Their Emerging Role in Co- Creating

More information

Alberta Health Services and Advancing Uptake of HTA & Innovation

Alberta Health Services and Advancing Uptake of HTA & Innovation Alberta Health Services and Advancing Uptake of HTA & Innovation Don Juzwishin, Candis Bilyk, Rosmin Esmail, Paule Poulin, Dr. Trevor Schuler April 5, 2011 Vancouver, British Columbia Objectives Introduction

More information

Changing landscape - changing paradigms

Changing landscape - changing paradigms IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute

More information

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE?

IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? IP7: CHANGING PARADIGM IN THE EVALUATION OF THE VALUE OF MEDICAL DEVICES: WHAT MUST STAKEHOLDERS EXPECT IN THE NEW DECADE? Department director Øyvind Melien Assessment interventions, Norwegian Institute

More information

Security and Risk Assessment in GDPR: from policy to implementation

Security and Risk Assessment in GDPR: from policy to implementation Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is

More information

Annotated Chapter Outline

Annotated Chapter Outline Annotated Chapter Outline Chapter 1: Context, Scope and Approach 1. Context. Access-poverty-economy linkages, need for substantive scale-up, global movement SE4ALL, SDGs, etc. 2. Rationale. Complementary

More information

Impact Case Study Template. Guidance Document

Impact Case Study Template. Guidance Document Guidance Document I. Introduction The College of Arts, Celtic Studies and Social Sciences (CACSSS) at UCC has an excellent record in fostering and sustaining high quality research at the forefront of international

More information

The digital and trustworthy evidence ecosystem: how can health industry players join to increase value in health care and capture a global market?

The digital and trustworthy evidence ecosystem: how can health industry players join to increase value in health care and capture a global market? The digital and trustworthy evidence ecosystem: how can health industry players join to increase value in health care and capture a global market? Per Olav Vandvik, Professor of Medicine, University of

More information

Zayna Khayat, PhD., MaRS, Canada

Zayna Khayat, PhD., MaRS, Canada Zayna Khayat, PhD., MaRS, Canada MaRSMission: improve public health & Improve health system performance, & drive the new health economy Senior Advisor, Director of EXCITE program pre-market health technology

More information

Randomized Evaluations in Practice: Opportunities and Challenges. Kyle Murphy Policy Manager, J-PAL January 30 th, 2017

Randomized Evaluations in Practice: Opportunities and Challenges. Kyle Murphy Policy Manager, J-PAL January 30 th, 2017 Randomized Evaluations in Practice: Opportunities and Challenges Kyle Murphy Policy Manager, J-PAL January 30 th, 2017 Overview Background What is a randomized evaluation? Why randomize? Advantages and

More information

What s Ethics Got to Do

What s Ethics Got to Do What s Ethics Got to Do with Big Data? WHO University of Miami Ethics Consultation October 12, 2017 Eric M. Meslin, Ph.D., FCAHS President & CEO Council of Canadian Academies Eric M. Meslin, PhD, FCAHS

More information

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements

SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM. New ideas & Improvements SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource Tool Box Regional Clinical

More information

Managing Projects, Managing Knowledge

Managing Projects, Managing Knowledge Managing Projects, Managing Knowledge Loughborough University, KM Module 2017 Energy Technologies Institute LLP The information in this document is the property of Energy Technologies Institute LLP and

More information

Technology and Innovation in the NHS Highlands and Islands Enterprise

Technology and Innovation in the NHS Highlands and Islands Enterprise Technology and Innovation in the NHS Highlands and Islands Enterprise Introduction Highlands and Islands Enterprise (HIE) welcomes the opportunity to respond to the Committee s call for views. We recognise

More information

Assessment element tables

Assessment element tables 1 of 36 20.10.2011 17:13 Assessment element tables The EUnetHTA Joint Action is supported by a grant from the European Commission 1 Health Problem and Current Use of the Technology 2 Description and technical

More information

e-care Living Lab - 5 avenue du Grand Sablon La Tronche - FRANCE Tel: +33 (0)

e-care Living Lab - 5 avenue du Grand Sablon La Tronche - FRANCE Tel: +33 (0) e-care Living Lab e-care Living Lab in Rhône-Alpes Region e-care got the Living Lab label in 2010 from ENoLL e-care Living Lab objectives (1/2) To promote the Living Lab approach in the healthcare sector

More information

Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value

Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value CADTH 2018 2021 STRATEGIC PLAN Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value Health care costs an estimated $242 billion annually

More information

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E5 Implementation Working Group & (R1) Current version dated June 2, 2006 ICH Secretariat,

More information

Integrated Scientific Advice Workshop: ISPOR Glasgow

Integrated Scientific Advice Workshop: ISPOR Glasgow Integrated Scientific Advice Workshop: ISPOR Glasgow Early Integrated Scientific Advice in Product Development: Get Real and Adapt to Accelerate Patient Access ICONplc.com Overview At today s patient-centered

More information

Health Technology Assessment (HTA) Dr Hamid Ravaghi

Health Technology Assessment (HTA) Dr Hamid Ravaghi Health Technology Assessment (HTA) Dr Hamid Ravaghi Why? What? How? 3 Why? New technologies Cost of new technologies Limited resources Ethical questions WHAT? Health Technology Instruments, equipment,

More information

Access to Medicines, Patent Information and Freedom to Operate

Access to Medicines, Patent Information and Freedom to Operate TECHNICAL SYMPOSIUM DATE: JANUARY 20, 2011 Access to Medicines, Patent Information and Freedom to Operate World Health Organization (WHO) Geneva, February 18, 2011 (preceded by a Workshop on Patent Searches

More information

Justice Select Committee: Inquiry on EU Data Protection Framework Proposals

Justice Select Committee: Inquiry on EU Data Protection Framework Proposals Justice Select Committee: Inquiry on EU Data Protection Framework Proposals Response by the Wellcome Trust KEY POINTS The Government must make the protection of research one of their priorities in negotiations

More information

EU Research Integrity Initiative

EU Research Integrity Initiative EU Research Integrity Initiative PROMOTING RESEARCH INTEGRITY IS A WIN-WIN POLICY Adherence to the highest level of integrity is in the interest of all the key actors of the research and innovation system:

More information

PHATE Population Health Assessment Engine

PHATE Population Health Assessment Engine PHATE Population Health Assessment Engine PHATE is a population health tool that provides clinicians with a fuller understanding of their patient population in the context of their community. When used

More information

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements

More information

Before I talk through the strategy itself, I want to tell you more about why

Before I talk through the strategy itself, I want to tell you more about why This presentation was given by Dr Annette Bramley, the Healthcare Technologies Theme leader. She thanked Professor Nelson and Professor Taylor for their presentations, and thanked everyone at the meeting

More information

Cheshire, Warrington and Wirral Area Team Commissioning for Value Pack

Cheshire, Warrington and Wirral Area Team Commissioning for Value Pack Cheshire, Warrington and Wirral Area Team Commissioning for Value Pack February 2014 NHS England Gateway ref: 00525 1 Contents Context 3 Introduction: The call to action.... 4 The approach Where to look

More information

Global Alliance for Genomics & Health Data Sharing Lexicon

Global Alliance for Genomics & Health Data Sharing Lexicon Version 1.0, 15 March 2016 Global Alliance for Genomics & Health Data Sharing Lexicon Preamble The Global Alliance for Genomics and Health ( GA4GH ) is an international, non-profit coalition of individuals

More information

EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES

EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES EXECUTIVE BOARD MEETING METHODOLOGY FOR DEVELOPING STRATEGIC NARRATIVES 1.Context and introduction 1.1. Context Unitaid has adopted

More information

Report of EPSRC Mathematical Sciences in Healthcare Scoping Meeting 15 SEPTEMBER 2014

Report of EPSRC Mathematical Sciences in Healthcare Scoping Meeting 15 SEPTEMBER 2014 Report of EPSRC Mathematical Sciences in Healthcare Scoping Meeting 15 SEPTEMBER 2014 Introduction and goals of the scoping meeting A small-scale scoping meeting was held on 15 th September 2014, to identify

More information

Health Technology Assessment for Medical Devices in Europe What has to be Considered. Position Paper

Health Technology Assessment for Medical Devices in Europe What has to be Considered. Position Paper Health Technology Assessment for Medical Devices in Europe What has to be Considered I. Executive Summary Position Paper The aim of this document is to position the medical device industry in Europe in

More information

Cross-border Flow of Health Information: is Privacy by Design sufficient to obtain complete and accurate data for Public Health in Europe?

Cross-border Flow of Health Information: is Privacy by Design sufficient to obtain complete and accurate data for Public Health in Europe? EUropean Best Information through Regional Outcomes in Diabetes Cross-border Flow of Health Information: is Privacy by Design sufficient to obtain complete and accurate data for Public Health in Europe?

More information

Ministry of Justice: Call for Evidence on EU Data Protection Proposals

Ministry of Justice: Call for Evidence on EU Data Protection Proposals Ministry of Justice: Call for Evidence on EU Data Protection Proposals Response by the Wellcome Trust KEY POINTS It is essential that Article 83 and associated derogations are maintained as the Regulation

More information

Medical Innovation Changing Business Models. Geneva, 5 July 2013

Medical Innovation Changing Business Models. Geneva, 5 July 2013 Medical Innovation Changing Business Models (A joint technical symposium by WHO, WIPO and WTO) Geneva, 5 July 2013 Richard Wilder Associate General Counsel Global Health Funding Options and IP Grants:

More information

Competition Regulation Innovation. Dr. Marisa Miraldo

Competition Regulation Innovation. Dr. Marisa Miraldo Competition Regulation Innovation Dr. Marisa Miraldo m.miraldo@imperial.ac.uk Brussels, 27th October, 2016 Outline The R&D and innovation challenge Current incentives HTA assessment: (weak) incentive for

More information

A Systematic Review of Challenges in Medical Tourism Destination Management

A Systematic Review of Challenges in Medical Tourism Destination Management University of Massachusetts Amherst ScholarWorks@UMass Amherst Tourism Travel and Research Association: Advancing Tourism Research Globally 2016 ttra International Conference A Systematic Review of Challenges

More information

Re-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s

Re-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s Re-engineering Collaborative Mechanisms and Knowledge Networks to Accelerate Innovation for Alzheimer s Richard A. Johnson Chairman, OECD/BIAC Science & Technology Committee National Academy of Sciences

More information

How can value be measured and assessed?

How can value be measured and assessed? Dávid Dankó, PhD, MSc Corvinus University of Budapest Institute of Management david.danko at uni-corvinus.hu How can value be measured and assessed? ISPOR 5 th Asia-Pacific Conference, Taipei, 2 September

More information

Innovations in Health: Approaches from the Regional Innovation Funds

Innovations in Health: Approaches from the Regional Innovation Funds The Young Foundation March 2010 Innovations in Health: Approaches from the Regional Innovation Funds Geoff Mulgan, Young Foundation with the Regional Innovation Funds Advisory Service (RIFAS) team March

More information

New Approaches to Safety and Risk Management

New Approaches to Safety and Risk Management New Approaches to Safety and Risk Management 15 18 May 2011 The 3rd DIA China Annual Meeting, Bejjin, China Ayman Ayoub MD MSC (med) Safety Surveillance & Risk Management Pfizer Disclaimer The views/opinions

More information

EU Cooperation on Health Technology Assessment

EU Cooperation on Health Technology Assessment Strategy for EU Cooperation on Health Technology Assessment Strategy for EU cooperation on Health Technology Assessment (HTA) The HTA Network is a voluntary network, set up by Directive2011/24 (article

More information

The General Data Protection Regulation and use of health data: challenges for pharmaceutical regulation

The General Data Protection Regulation and use of health data: challenges for pharmaceutical regulation The General Data Protection Regulation and use of health data: challenges for pharmaceutical regulation ENCePP Plenary Meeting- London, 22/11/2016 Alessandro Spina Data Protection Officer, EMA An agency

More information

Multi-criteria value-maximization methods for the prioritization of R&D investments in global health product development International Collaboration

Multi-criteria value-maximization methods for the prioritization of R&D investments in global health product development International Collaboration Multi-criteria value-maximization methods for the prioritization of R&D investments in global health product development International Collaboration for Capitalizing on Life-Saving and Cost- Effective

More information

Visualization of Systems and Stakeholders in Health Care Innovation by means of a Multilevel Design Model

Visualization of Systems and Stakeholders in Health Care Innovation by means of a Multilevel Design Model Visualization of Systems and Stakeholders in Health Care Innovation by means of a Multilevel Design Model Asli Boru 1,2, Peter Joore 1,2, Frido Smulders 1, Ate Dijkstra 2 and Richard Goossens 1,3 1 Delft

More information

Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice

Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice Webinar IMI2 Call 13 Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice 14 December 2017 10:30 CET Agenda How to use GoToWebinar Catherine

More information

SCIROCCO - Scaling Integrated Care in Context

SCIROCCO - Scaling Integrated Care in Context SCIROCCO - Scaling Integrated Care in Context Dr Andrea Pavlickova European Service Development Manager, NHS 24 ICIC 2016 23 May 2016, Barcelona SCIROCCO builds on the achievements of the European Innovation

More information